Tumor anemia
Conditions
Interventions
control group:Recombinant human erythropoietin injection (Jimaixin) 12000 IU/branch, one subcutaneous injection, three times a week (at least one day interval each time) for 8 weeks
experimental group:Recombinant human erythropoietin injection (Jimaixin) 12000 IU/branch, 3 branches per time, subcutaneous injection, once a week (3 branches per injection at different parts), for 8
Sponsors
Anyang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Patients with non-bone marrow malignant tumors (excluding leukemia and multiple myeloma) diagnosed by cytology/histology; 2) Chemotherapy-related anemia (Hb =60) and expected survival of more than 3 months; 4) patients weighing more than 45 kg; 5) Aged 18-70 years, gender-free, hospitalized or outpatient patients; 6) Voluntary subjects, patients who have signed the informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with breast cancer and head and neck cancer. 2) Anemia caused by iron, folic acid or B12 deficiency and metabolic disorders, hemolysis, acute or chronic blood loss or other non-chemotherapy causes (iron deficiency criteria: ferritin 160mmHg, DP > 110 mmHg) or severe infection. 9) Patients with severe primary diseases of heart, liver, kidney and hematopoietic system (ALT, AST > 2.5 times of the upper limit of normal value, Cr > the upper limit of normal value; ALT, AST > 3 times of the upper limit of normal value in patients with liver metastasis). 10) Those with neurological or mental disorders who are unable to cooperate or unwilling to cooperate. 11) Patients with previous history of thrombosis, abnormal coagulation function, hematological history or ineffective EPO treatment. 12) Patients with allergies and allergic constitutions to known ingredients of test or control drugs. 13) Pregnant, lactating women or recent patients with fertility plans. 14) Patients who have participated in other clinical trials in the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hemoglobin; | — |
Countries
China
Contacts
Public ContactWang Huixiao
Anyang Cancer Hospital
Outcome results
None listed